1099 related articles for article (PubMed ID: 34036623)
1. Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.
Yi C; Chen L; Lin Z; Liu L; Shao W; Zhang R; Lin J; Zhang J; Zhu W; Jia H; Qin L; Lu L; Chen J
Hepatology; 2021 Nov; 74(5):2544-2560. PubMed ID: 34036623
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of FGFR Reactivates IFNγ Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies.
Adachi Y; Kamiyama H; Ichikawa K; Fukushima S; Ozawa Y; Yamaguchi S; Goda S; Kimura T; Kodama K; Matsuki M; Miyano SW; Yokoi A; Kato Y; Funahashi Y
Cancer Res; 2022 Jan; 82(2):292-306. PubMed ID: 34753772
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma.
Torrens L; Montironi C; Puigvehí M; Mesropian A; Leslie J; Haber PK; Maeda M; Balaseviciute U; Willoughby CE; Abril-Fornaguera J; Piqué-Gili M; Torres-Martín M; Peix J; Geh D; Ramon-Gil E; Saberi B; Friedman SL; Mann DA; Sia D; Llovet JM
Hepatology; 2021 Nov; 74(5):2652-2669. PubMed ID: 34157147
[TBL] [Abstract][Full Text] [Related]
4. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway.
Kato Y; Tabata K; Kimura T; Yachie-Kinoshita A; Ozawa Y; Yamada K; Ito J; Tachino S; Hori Y; Matsuki M; Matsuoka Y; Ghosh S; Kitano H; Nomoto K; Matsui J; Funahashi Y
PLoS One; 2019; 14(2):e0212513. PubMed ID: 30811474
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model.
Kimura T; Kato Y; Ozawa Y; Kodama K; Ito J; Ichikawa K; Yamada K; Hori Y; Tabata K; Takase K; Matsui J; Funahashi Y; Nomoto K
Cancer Sci; 2018 Dec; 109(12):3993-4002. PubMed ID: 30447042
[TBL] [Abstract][Full Text] [Related]
6. Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma.
Deng H; Kan A; Lyu N; He M; Huang X; Qiao S; Li S; Lu W; Xie Q; Chen H; Lai J; Chen Q; Jiang X; Liu S; Zhang Z; Zhao M
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34168004
[TBL] [Abstract][Full Text] [Related]
7. Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody.
Liu G; Zhou W; Li X; Guo L; He T; Zhao J; Gong L
Front Immunol; 2021; 12():712351. PubMed ID: 34504494
[TBL] [Abstract][Full Text] [Related]
8. Blocking Triggering Receptor Expressed on Myeloid Cells-1-Positive Tumor-Associated Macrophages Induced by Hypoxia Reverses Immunosuppression and Anti-Programmed Cell Death Ligand 1 Resistance in Liver Cancer.
Wu Q; Zhou W; Yin S; Zhou Y; Chen T; Qian J; Su R; Hong L; Lu H; Zhang F; Xie H; Zhou L; Zheng S
Hepatology; 2019 Jul; 70(1):198-214. PubMed ID: 30810243
[TBL] [Abstract][Full Text] [Related]
9. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
10. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
11. Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling.
Shigesawa T; Maehara O; Suda G; Natsuizaka M; Kimura M; Shimazaki T; Yamamoto K; Yamada R; Kitagataya T; Nakamura A; Suzuki K; Ohara M; Kawagishi N; Umemura M; Nakai M; Sho T; Morikawa K; Ogawa K; Ohnishi S; Sugiyama M; Mizokami M; Takeda H; Sakamoto N
Carcinogenesis; 2021 Feb; 42(1):58-69. PubMed ID: 32449510
[TBL] [Abstract][Full Text] [Related]
12. FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2.
Xie M; Lin Z; Ji X; Luo X; Zhang Z; Sun M; Chen X; Zhang B; Liang H; Liu D; Feng Y; Wang Y; Li Y; Liu B; Huang W; Xia L
J Hepatol; 2023 Jul; 79(1):109-125. PubMed ID: 36907560
[TBL] [Abstract][Full Text] [Related]
13. siRNA targeting PD-L1 delivered with attenuated Salmonella enhanced the anti-tumor effect of lenvatinib on mice bearing Hepatocellular carcinoma.
Chen P; Li Y; Wei P; Liang L; Li B; Cao Y; Han X; Wang Y; Duan X; Jia H; Zhao T; Ren J
Int Immunopharmacol; 2022 Oct; 111():109127. PubMed ID: 35964407
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study.
Chen S; Xu B; Wu Z; Wang P; Yu W; Liu Z; Huang X; Wu Y; Li T; Guo W
BMC Cancer; 2021 Oct; 21(1):1126. PubMed ID: 34670506
[TBL] [Abstract][Full Text] [Related]
15. Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein-1 inhibitors: A promising treatment approach for high-burden hepatocellular carcinoma.
Fu S; Xu Y; Mao Y; He M; Chen Z; Huang S; Li D; Lv Y; Wu J
Cancer Med; 2024 May; 13(9):e7105. PubMed ID: 38686567
[TBL] [Abstract][Full Text] [Related]
16. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models.
Matsuki M; Hoshi T; Yamamoto Y; Ikemori-Kawada M; Minoshima Y; Funahashi Y; Matsui J
Cancer Med; 2018 Jun; 7(6):2641-2653. PubMed ID: 29733511
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of CMTM4 Sensitizes Cholangiocarcinoma and Hepatocellular Carcinoma to T Cell-Mediated Antitumor Immunity Through PD-L1.
Chui NN; Cheu JW; Yuen VW; Chiu DK; Goh CC; Lee D; Zhang MS; Ng IO; Wong CC
Hepatol Commun; 2022 Jan; 6(1):178-193. PubMed ID: 34558800
[TBL] [Abstract][Full Text] [Related]
18. The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma.
Kanzaki H; Chiba T; Ao J; Koroki K; Kanayama K; Maruta S; Maeda T; Kusakabe Y; Kobayashi K; Kanogawa N; Kiyono S; Nakamura M; Kondo T; Saito T; Nakagawa R; Ogasawara S; Suzuki E; Ooka Y; Muroyama R; Nakamoto S; Yasui S; Tawada A; Arai M; Kanda T; Maruyama H; Mimura N; Kato J; Zen Y; Ohtsuka M; Iwama A; Kato N
Sci Rep; 2021 Mar; 11(1):5303. PubMed ID: 33674622
[TBL] [Abstract][Full Text] [Related]
19. Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma.
Langhans B; Nischalke HD; Krämer B; Dold L; Lutz P; Mohr R; Vogt A; Toma M; Eis-Hübinger AM; Nattermann J; Strassburg CP; Gonzalez-Carmona MA; Spengler U
Cancer Immunol Immunother; 2019 Dec; 68(12):2055-2066. PubMed ID: 31724091
[TBL] [Abstract][Full Text] [Related]
20. Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications.
Sun X; Zhang Q; Mei J; Yang Z; Chen M; Liang T
BMC Cancer; 2022 Mar; 22(1):293. PubMed ID: 35305593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
